A5072421835- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Gastric Cancer Management and Outcomes
- Medical Imaging Techniques and Applications
- Hepatocellular Carcinoma Treatment and Prognosis
- Inflammatory Biomarkers in Disease Prognosis
- Advanced Radiotherapy Techniques
- Metastasis and carcinoma case studies
- Multiple and Secondary Primary Cancers
- Brain Metastases and Treatment
- Lymphoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Head and Neck Cancer Studies
- Cancer Diagnosis and Treatment
- Cancer Cells and Metastasis
- Cancer-related molecular mechanisms research
- Bladder and Urothelial Cancer Treatments
- Glioma Diagnosis and Treatment
- Ultrasound and Hyperthermia Applications
- Effects of Radiation Exposure
- Management of metastatic bone disease
- Frailty in Older Adults
LMU Klinikum
2017-2025
Ludwig-Maximilians-Universität München
2017-2025
University Children's Hospital Tübingen
2024
Deutschen Konsortium für Translationale Krebsforschung
2019
University Radiology
2018
The aim of this prospective study is to evaluate the clinical use and real-world efficacy durvalumab maintenance treatment after chemoradiotherapy (CRT) in unresectable stage, locally advanced non-small cell lung cancer (NSCLC). All consecutive patients with unresectable, NSCLC PD-L1 expression (≥1%) treated October 2018 were included. Regular follow up, including physical examination, PET/CT and/or contrast-enhanced CT-Thorax/Abdomen performed every three months CRT. Descriptive pattern...
mmune checkpoint inhibition (CPI) has an increasing impact in the multimodal treatment of locally advanced non-small cell lung cancer (LA-NSCLC). Increasing evidence suggests outcome depending on tumor PD-L1 expression. The purpose this retrospective study was to investigate prognostic value expression cells combination with CD8+ stroma-infiltrating lymphocyte (TIL) density inoperable LA-NSCLC treated concurrent chemoradiotherapy (CRT).We retrospectively assessed clinical characteristics and...
Concurrent chemoradiotherapy (CRT) followed by maintenance treatment with the PD-L1 inhibitor durvalumab is a new standard of care for inoperable stage III NSCLC. The present study compares oncological outcome patients treated CRT to those and (CRT-IO) in real-world setting. analysis was performed based on retro- prospectively collected data 144 consecutive NSCLC between 2011–2020. Local-regional-progression-free-survival (LRPFS—defined as progression mediastinum, hilum and/or...
Abstract Background We explored the dynamic changes of major leukocyte subsets during definitive treatment patients with inoperable stage II/III NSCLC lung cancer and correlated it to survival identify subpopulations associated maximal patient benefit. Methods analyzed peripheral blood 20 patients, either treated thoracic radiotherapy (RT), concurrent chemo-radiotherapy (cCRT), or cCRT additional immune-checkpoint inhibition therapy. Peripheral was collected at 9 timepoints before, during,...
Abstract Background Loco-regional and distant failure are common in inoperable stage III non small-cell lung cancer (NSCLC) after chemoradiotherapy (CRT). However, there is limited real-world data on pattern, patient prognosis salvage options. Methods We analysed 99 consecutive patients with NSCLC treated CRT between 2011 2016. Follow up CT scans from date of the first-site were matched delivered radiation treatment plans. Intra-thoracic loco-regional relapse was defined as in-field (IFR)...
Patient performance scores are used widely in clinical practice to assess a patient's general condition. The aim of this study was evaluate the prognostic role Eastern Cooperative Oncology Group score (ECOG PS) before, after and its changes during chemoradiotherapy patients with stage III non-small cell lung cancer (NSCLC).Records 99 NSCLC were evaluated. ECOG PS analyzed for impact on overall (OS) event-free (EFS) survival.Median OS considering entire cohort 20.8 months (range=15.3-26.2...
Abstract Purpose In patients with unresectable stage III non-small-cell lung cancer (NSCLC), durvalumab maintenance treatment after chemoradiotherapy (CRT) significantly improves survival. So far, however, metabolic changes of tumoral lesions and secondary lymphoid organs under are unknown. Hence, we assessed on [ 18 F]FDG PET/CT in comparison to undergoing CRT alone. Methods Forty-three both before standard for NSCLC were included, 16/43 was initiated (CRT-IO) prior the second PET/CT....
Stage III non-small cell lung cancer (NSCLC) represents a heterogeneous disease regarding principal patient- and tumor characteristics. A simple score may aid in personalizing multimodal therapy.The data of 99 consecutive patients with performance status ECOG 0-1 treated until the end 2016 approach for inoperable NSCLC (UICC 7th edition stage IIIA/B) were evaluated. Patient- tumor-related factors examined their impact on overall survival. Factors showing negative association prognosis then...
Inoperable stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous patient cohort. Multimodal treatment approaches including radiotherapy have been the new standard of care, with promising outcomes. The planning target volume (PTV), primary tumor, involved lymph node stations and safety margins, can vary widely. In order to evaluate impact PTV for overall survival (OS), progression-free (PFS) loco-regional control, we analyzed retrospective prospective data 122...
Abstract Purpose/aim The international standard for patients with large inoperable stage III NSCLC is durvalumab consolidation after concurrent chemoradiotherapy (CRT). In this single centre observational study based on individual data, we prospectively evaluated the role of concurrent/sequential versus sequential immune checkpoint inhibition (ICI). Methods and total, 39 were enrolled, 11 (28%) treated simultaneous therapy PD-1 (nivolumab) (SIM-cohort) 28 (72%) received PD-L1 (durvalumab) as...
Stereotactic radiosurgery/radiotherapy (SRS/SRT) and novel systemic treatments, such as tyrosine kinase inhibitors (TKIs) immune checkpoint (ICIs), have demonstrated to be effective in managing brain metastases non-small cell lung cancer (NSCLC). However, the optimal treatment sequence of SRS/SRT TKI/ICI remains uncertain. This retrospective monocentric analysis addresses this question by comparing outcomes patients with NSCLC who received upfront versus those were initially treated TKI/ICI.
To determine the feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation (Hypo-IGRT) in locally advanced node-positive non-small cell lung cancer patients with highly compromised pulmonary function.Eight highly-selected and closely monitored diminished function (FEV1 ≤ 1.0 L and/or DLCO-SB 40% on long-term oxygen therapy) were treated Hypo-IGRT. Planning was based 18F-FDG-PET/CT 4D-CT treatment position. Hypo-IGRT delivered to a total dose 45 Gy (ICRU) 15...
The present study evaluates outcome after chemoradiotherapy (CRT) with concurrent and/or sequential Programmed Cell Death 1 (PD-1) or Ligand (PD-L1) immune checkpoint inhibition (CPI) for inoperable stage III NSCLC patients depending on planning target volume (PTV).Prospective data of thirty-three consecutive treated CRT and durvalumab (67%, 22 patients) nivolumab (33%, 11 were analyzed. Different PTV cut offs as a continuous variable evaluated their association progression-free (PFS),...
Background/Aim: Previous studies have suggested the prognostic value of Lung Immune Prediction Index (LIPI) and Gustave Roussy Score (GRIM) as markers in advanced small cell lung cancer (SCLC). However, LIPI GRIM score not been evaluated patients with limited stage SCLC (LS-SCLC). Patients Methods: Pretreatment 33 (43%) out 77 LS-SCLC treated chemoradiotherapy (CRT) during 2004-2015 were included. Results: The median overall survival (OS) time good, intermediate, poor subgroups 14, 17 3...
Background The objective of this study was to investigate the feasibility and efficacy image‐guided moderately hypofractionated thoracic radiotherapy (hypo‐IGRT) in patients with non–small cell lung cancer (NSCLC) poor performance status severely limited pulmonary function reserve. Methods Consecutive inoperable who had node‐positive, stage IIB‐IIIC (TNM, 8th edition) or recurrent NSCLC, an Eastern Cooperative Oncology Group ≥1, a forced expiratory volume 1 second (FEV ) ≤1.0 L,...
Background: Durvalumab as maintenance treatment after platinum-based concurrent chemoradiotherapy (cCRT) has become the standard of care in inoperable stage III non-small cell lung cancer (NSCLC). In this nationwide survey, we solicited members German Radiation Oncology Society to review current distribution and clinical settings durvalumab cCRT, observed side effects summarize follow-up management. Methods: We surveyed radiation oncology institutions Germany via an anonymous online...
The PET-derived metabolic tumor volume (MTV) is an independent prognosticator in non-small cell lung cancer (NSCLC) patients. We analyzed the prognostic value of residual MTV (rMTV) after completion chemoradiotherapy (CRT) inoperable stage III NSCLC patients with and without immune checkpoint inhibition (ICI).Fifty-six (16 female, median 65.0 years) underwent 18F-FDG PET/CT standard CRT. rMTV was delineated on using a threshold (liver SUVmean + 2 × deviation). 21/56 additional ICI (CRT-IO,...